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ABSTRACT
Objective: Generic, preference-based health-related quality of life
(HRQoL) instruments is increasingly used in health-care decision-making
process. However, to our knowledge, no such HRQoL instrument has
been validated or used in chronic prostatitis. We therefore aimed to assess
and compare the psychometric properties of EuroQol (EQ-5D) and Short
Form 6D (SF-6D) among chronic prostatitis patients in China.
Methods: Consenting patients were interviewed using EQ-5D and SF-6D.
Convergent and discriminative construct validities were examined with
ﬁve and two a priori hypotheses, respectively. Sensitivity was compared
using receiver operating characteristic (ROC) curves and relative efﬁciency
(RE) statistics. Agreement between instruments was assessed with intra-
class correlation coefﬁcients and Bland–Altman plot, while factors affect-
ing utility difference were explored with multiple liner regression models.
Results: In 268 subjects, mean (SD) EQ-5D and SF-6D utility scores were
comparable at 0.73 (0.15) and 0.75 (0.10), respectively. Five of the seven
hypotheses for construct validity were fulﬁlled in both instruments. The
areas under ROC of them all exceeded 0.5 (P < 0.001). SF-6D had 9.7–
19.9% higher efﬁciency than EQ-5D at detecting the difference in chronic
prostatitis symptom severity. Despite no signiﬁcant difference in utility
scores between two instruments, lack of agreement was observed with low
intraclass correlation coefﬁcient (0.218–0.630) and Bland–Altman plot
analysis. Chronic prostatitis symptom severity signiﬁcantly (P < 0.05)
inﬂuenced differences in utility scores between EQ-5D and SF-6D.
Conclusions: Both EQ-5D and SF-6D are demonstrated to be valid and
sensitive HRQoL measures in Chinese chronic prostatitis patients, with
SF-6D showing better HRQoL dimension coverage, greater sensitivity,
lower ceiling effect, and more rational distribution. Further research is
needed to determine longitudinal response and reliability.
Keywords: China, chronic prostatitis, EQ-5D, SF-6D, utility, validation
study.
Introduction
Health related-quality of life (HRQoL) has been recognized
increasingly as an important outcome of health care to be incor-
porated into the decision-making process of clinicians and poli-
cymakers, especially in the management of patients with chronic
diseases or disorders [1]. Nevertheless, to adopt a more holistic
patient management approach by including HRQoL as an
outcome clinically, the major challenge is to ﬁnd valid and reli-
able HRQoL measures.
Generally speaking, HRQoL can be evaluated using either
condition-speciﬁc or generic instruments. Although the advan-
tage of condition-speciﬁc measures is their capacity to detect
small, but clinically important changes in a disease, these instru-
ments are not suitable for comparisons across different disease
states. In contrast, generic HRQoL measures include a broader
range of health dimensions and enable broader comparisons to
be made independent of disease groups, treatments, or health
programs [2]. Hence, it is recommended that a generic instru-
ment should be used alongside a disease-speciﬁc instrument in
evaluating HRQoL in clinical settings. Furthermore, the use of
generic preference-based measures instead of proﬁle-based mea-
surement system can provide utility scores for calculating quality
adjusted life-years, which is a widely used clinical effectiveness
indicator [3]. Indeed, quality adjusted life-years has been for-
mally included into methodological guidelines for health tech-
nology assessment in many countries [4–6].
Chronic prostatitis (CP) is a common condition affecting
2–10% of men around the world [7,8] and 4.5% in China [9],
and causes quality of life impairment of its sufferers [10,11].
Since CP is primarily a disease of uncertain etiology with no
current “gold standard” for its treatment, the primary goal of CP
management is to achieve optimal symptom control and ulti-
mately to improve the patients’ HRQoL. As such, HRQoL
proﬁle measures such as Sickness Impact Proﬁle, Short Form 36
and CP-speciﬁc measure, National Institutes of Health Chronic
Prostatitis Symptom Index (NIH-CPSI) are commonly used
generic and disease-speciﬁc proﬁle measures for CP patients [12].
However, gaps are noted in the management of CP patients
compared with other quality-of-life diseases, such as rheumatoid
arthritis [13]. First, the quantity of publications on HRQoL of
CP patients is limited [12]. Second, at present, to our best knowl-
edge, no preference-based HRQoL instrument has been validated
or used in CP. Our objective of this study, therefore, was to
evaluate the validity and sensitivity of EuroQol (EQ-5D) and
Short Form 6D (SF-6D), two preference-based HRQoL instru-
ments increasingly used in clinical settings, in CP patients. Fur-
thermore, considering the debate on the different performance of
EQ-5D and SF-6D and the dilemma of choosing among instru-
ments [14], a secondary objective was to evaluate and compare
the difference between these two instruments to provide some
baseline information for the use of them in CP patients.
Methods
Study Design and Patient Recruitment
To increase the power and representativeness, this cross-sectional
study was conducted in two centers, namely, the 306th Hospital
of PLA in Beijing (northern China) and the First People’s Hos-
pital of Yunnan Province in Kunming (southern China), two
Address correspondence to: Shu-Chuen Li, Discipline of Pharmacy and
Experimental Pharmacology, School of Biomedical Sciences and Phar-
macy, University of Newcastle, Callaghan, NSW 2308, Australia. E-mail:
ShuChuen.Li@newcastle.edu.au
10.1111/j.1524-4733.2010.00728.x
*These senior authors contributed equally to this study.
Volume 13 • Number 5 • 2010
V A L U E I N H E A LT H
© 2010, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/10/649 649–656 649
tertiary referral hospitals in China. With informed consent, a
consecutive sample of outpatients with CP was recruited in this
Institutional Review Board-approved study from December 2008
to March 2009. Patients were eligible if they were aged between
20 and 59 years and diagnosed with CP by their attending
physicians based on clinical symptom, microscopic examination
of expressed prostatic secretion and urine, and transrectal ultra-
sound features. Each patient was interviewed by a trained inter-
viewer using a standardized questionnaire containing the EQ-5D/
visual analog scale (VAS) and SF-6D. Other information solicited
from the participants included their sociodemographic data and
medical conditions. The symptom severity of the patients was
measured using the NIH-CPSI. The interviewer, procedure, and
questionnaire used were identical between two cities.
Instruments
EQ-5D/VAS: The EQ-5D is a generic, preference-based HRQoL
instrument with ﬁve dimensions, including mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression. Each
dimension has three response levels (no problem, some problems,
and severe problems). The EQ-5D descriptive system can theo-
retically generate 243 health states, each of which was assigned a
utility score ranging from -0.59 to 1.00. The utility scoring
algorithm adopted in this study was developed using time trade-
off (TTO)-based preference scores from a UK general population
sample [15]. EQ-VAS is a 20-cm vertical visual analog scale
ranging from 100 (best imaginable health state) to 0 (worst
imaginable health state) to represent the overall health. Respon-
dents classify and rate their health status on the day of the survey.
The simpliﬁed Chinese version of EQ-5D/VAS in this study is an
ofﬁcial version authorized by the EuroQol Group.
SF-6D
The SF-6D was developed from Short Form 36 by Brazier et al.
with six dimensions comprising physical functioning, role limi-
tations, social functioning, pain, mental functioning and vitality
[16]. Each dimension has 4 to 6 levels and thus 18,000 possible
health states are deﬁned. The SF-6D utility scoring algorithm
used in this study was derived from a representative sample of
UK general population with Standard Gambling (SG) method,
raging from 0.29 to 1.00 [16]. The recall period is 4 weeks. Our
study adopted the Hong Kong Chinese version of SF-6D trans-
lated and validated in general population by Lam et al. in Hong
Kong [17]. The traditional Chinese characters used in the Hong
Kong Chinese SF-6D were converted into equivalent simpliﬁed
Chinese characters used in Mainland China. During our study,
subjects did not report any concerns regarding phrasing of the
Hong Kong Chinese SF-6D.
NIH-CPSI
The NIH-CPSI, a nine-item index, is a commonly used instru-
ment for assessing symptoms and its impact on daily life in men
with CP/CPPS [18,19]. The score of NIH-CPSI range from 0 to
43, comprising three subscores, including pain (21 scores),
urinary symptoms (10 scores), and quality of life (12 scores).
NIH-CPSI has been accepted by the International Prostatitis
Collaborative Network as the standard, valid instrument for
evaluating men with chronic prostatitis symptoms [18,20]. The
Chinese NIH-CPSI has been validated and used wildly in scien-
tiﬁc research and clinical observation [7,21].
Data Analyses
Descriptive statistics. All analyses were based on subjects who
fully completed the questionnaire. Descriptive statistics were
computed to characterize the sample and the distribution of
EQ-5D/VAS and SF-6D. Continuous variables are presented as
mean, standard deviation (SD), median, interquartile range
(IQR), and range while categorical variables are shown in the
number and proportion of the sample within each group. As we
recruited the study subjects from two centers in Beijing and
Kunming, accordingly, we compared the sample composition
based on the socioeconomic and clinical characteristic between
two cities with Mann–Whitney U or chi-square tests. In the
further analyses, we combined the data from two cities together
to increase the power.
Construct validation. Convergent validity of the EQ-5D and
SF-6D was assessed by examining their association with NIH-
CPSI and EQ-VAS at domain and scale level. Based on the
literature and clinical experience, six a priori hypotheses were
generated where moderate-to-strong correlation coefﬁcients (r)
were expected, namely: 1) EQ-5D and SF-6D utility scores with
total NIH-CPSI scores; 2) EQ-5D and SF-6D utility scores with
NIH-CPSI quality of life domain; 3) EQ-5D and SF-6D utility
scores with EQ-VAS; 4) EQ-5D and SF-6D pain/discomfort with
NIH-CPSI pain; and 5) EQ-5D usual activity, SF-6D role limita-
tion with NIH-CPSI pain, urinary. Validity coefﬁcient were com-
puted as Spearman’s rank correlation coefﬁcient (r), with r > 0.5
considered as strong correlation, 0.35 to 0.5 as moderate corre-
lation, and 0.2 to 0.34 as week correlation [22].
As a further test of validity, we used “known-group” method
to examine the discriminative validity of EQ-5D and SF-6D
based on its ability to discriminate patients with different level of
CP severity and self-reported health status groups. Subjects with
more severe symptom and poorer health status were hypoth-
esized to have lower utility scores for these two instruments.
Other variables used in assessing validity include the social eco-
nomic status, duration of CP, and presence of other medical
conditions. Nonparametric Mann–Whitney U tests were per-
formed to identify statistically signiﬁcant effects of the dichoto-
mous variables on utility scores, while Kruskal–Wallis H tests for
polytomous variables. The levels of CP severity were deﬁned as
mild, moderate, and severe if NIH-CPSI scores ranged from 0 to
14, 15 to 30, and 31 to 43, respectively [23,9]. EQ-VAS was
adopted as an indicator for self-reported health status, and we
classiﬁed the EQ-VAS scores into four groups, namely <65 (bad),
65 to 79 (fair), 80 to 89 (good), and 90 to 100 (excellent) [24].
Sensitivity of EQ-5D and SF-6D. The efﬁciency of the EQ-5D
and SF-6D to detect clinically relevant differences of CP patients
were compared using relative efﬁciency (RE) statistic and receiver
operating characteristic (ROC) curves. The area under ROC
curves (AUC) was computed to compare the discriminative prop-
erties of these two instruments [25]. The measure that generates
the largest AUC is regarded as the most sensitive as an instrument
with ideal discriminative ability has an AUC of 1.0, and an AUC
0.5 means no discriminative power. RE is based on the ratio of
squared t statistics between two instruments, where EQ-5D was
deﬁned as the denominator [25,26]. The coefﬁcient greater than
1 suggests that SF-6D is more sensitive than EQ-5D at detecting
clinically relevant differences with the given sample size, while
the coefﬁcient less than 1 means less sensitive. For the purpose of
AUC and RE calculation, NIH-CPSI scores were dichotomized
into two categories:14 and15, indicating mild and moderate
to severe CP severity, respectively. Considering the choice of
cutoff point is unavoidably arbitrary and may have effect on the
computation results, the RE and AUC were also computed using
the median of NIH-CPSI score as an alternative cutoff point.
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Level of agreement between EQ-5D and SF-6D. We compared
the mean (SD) and median (IQR) utility scores between these two
instruments across the sample, as well as for subgroups catego-
rized by social economic and clinical characteristic. Paired com-
parisons were made with Wilcoxon’s signed rank test and
Spearman’s rank correlation for the association between them.
Small subgroups (n < 10) were combined with the adjacent
group. Given the limitations of simple correlation and signiﬁ-
cance test, the degree of agreement between utility scores of
EQ-5D and SF-6D was assessed by intraclass correlation coefﬁ-
cient (ICC) and Bland–Altman plot. The ICC was computed with
two-way random effects model based on absolute agreement and
coefﬁcient above 0.7 suggests an strong agreement [26]. In
Bland–Altman plot, the average of the two measurements was
plotted on the x-axis, and the difference between the two mea-
surements on the y-axis, where SF-6D was the subtrahend. The
deviation of difference from 0, where implies total agreement,
indicates the degree of agreement for each subject on the plot
[27].
Factors affecting utility difference between EQ-5D and
SF-6D. We explored whether patients’ socioeconomic and clini-
cal characteristics were related to the utility difference between
EQ-5D and SF-6D. Thus, we ran multiple liner regression (MLR)
where the utility difference was the dependent variable.
Individual characteristics including age, place, ethnicity, educa-
tion level, marriage and working status, months with CP, pres-
ence with chronic or acute medical conditions, NIH-CPSI scores
and EQ-VAS for global well-being were treated as independent
variables. All analyses were based on subjects who fully com-
pleted the questionnaire. Statistical analyses were performed
using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Characteristics of Patients
Of 275 patients who participated, 5 patients from Beijing and 2
patients from Kunming failed to complete the questionnaire
because of personal reason and were thus excluded from the
analyses. In the remaining 268 patients with median age of 32
years (ranging 20–59), 173 were interviewed at Beijing and 95 at
Kunming.
The patients from Beijing had fewer ethnic minorities, higher
education level, and smaller household size (P < 0.05), which
were representative of these two cities (Table 1) [28]. No signiﬁ-
cant difference was detected in other demographic and clinical
characteristics of patients between two cities, and the demo-
graphic and disease proﬁle of the analyzed sample closely
resembled the results of epidemiological survey of CP patients in
China by Liang et al. (Table 1) [21].
Table 1 Characteristics of patients and distribution of EQ-5D and SF-6D utility scores
Characteristic Total (n = 268) Beijing (n = 173) Kunming (n = 95) P-value
Age (years) 0.494
Median (IQR) 32.0 (10.0) 31.0 (10.0) 33.0 (9.0)
Mean (SD) 33.2 (7.99) 33.1 (8.24) 33.3 (7.57)
Range 20.0 to 59.0 21.0 to 59.0 20.0 to 52.0
Ethnic minority 26 (9.7) 7 (4.0) 19 (20.0) <0.001
Years of education 0.011
6 18 (6.7) 10 (5.8) 8 (8.4)
7–12 118 (44.0) 66 (38.2) 52 (54.7)
12 132 (49.3) 97 (56.1) 35 (36.8)
Married 164 (61.2) 101 (58.4) 63 (66.3) 0.202
Working 218 (81.3) 146 (84.4) 72 (75.8) 0.084
Household size
Median (IQR) 3.0 (1.0) 3.0 (2.0) 4.0 (1.0) 0.001
Presence of chronic medical condition* 59 (22.0) 40 (23.1) 19 (20.0) 0.555
Presence of acute medical condition† 135 (50.4) 87 (50.3) 48 (50.5) 0.970
Months with CP 0.035
6 106 (39.5) 75 (43.4) 31 (32.6)
7–12 55 (20.5) 33 (19.1) 22 (23.2)
13–18 39 (14.6) 27 (15.6) 12 (12.6)
19–24 26 (9.7) 19 (11.0) 7 (7.4)
24 42 (15.7) 19 (11.0) 23 (24.2)
NIH-CPSI 0.264
Median (IQR) 18.0 (7.8) 19.0 (8.0) 17.0 (6.0)
Mean (SD) 18.5 (5.75) 18.8 (5.67) 17.9 (5.89)
Range 6.0 to 34.0 6.0 to 34.0 6.0 to 34.0
EQ-VAS 0.757
Median (IQR) 70.0 (20.0) 70.0 (20.0) 70.0 (20.0)
Mean (SD) 69.15 (14.20) 68.98 (13.28) 69.45 (15.8)
Range 30.0 to 100.0 30.0 to 100.0 40.0 to 100.0
EQ-5D 0.402
Median (IQR) 0.73 (0.07) 0.73 (0.07) 0.73 (0.07)
Mean (SD) 0.73 (0.15) 0.74 (0.14) 0.72 (0.16)
Range 0.19 to 1 0.19 to 1 0.29 to 1
SF-6D 0.357
Median (IQR) 0.76 (0.14) 0.76 (0.12) 0.79 (0.16)
Mean (SD) 0.75 (0.10) 0.75 (0.09) 0.75 (0.11)
Range 0.44 to 0.95 0.53 to 0.95 0.44 to 0.93
*Self-reported chronic medical conditions included diabetes mellitus, hypertension, heart disease, stroke, asthma or lung diseases, bone or muscle illnesses, and mental illnesses.
†Self-reported acute medical conditions included upper respiratory tract infections, vomiting, diarrhea, headache, insomnia and injuries. Recall periods are 4 weeks.
n (%) unless otherwise stated.
EQ-5D, EuroQol; SF-6D, Short Form 6D.
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Description Statistics of EQ-5D and SF-6D
Of the total 268 patients, the mean (SD) utility score for the
EQ-5D was 0.73 (0.15), and the median (IQR) was 0.73 (0.07),
while the mean (SD) utility score was 0.75 (0.10) for SF-6D, and
the median (IQR) was 0.76 (0.14). Utility scores between two
cities were not signiﬁcantly different. The range of EQ-5D utility
score was 0.19 to 1, wider than the range SF-6D, from 0.44 to
0.95 (Table 1).
Kolmogorov–Smirnov normal test results showed that distri-
bution of SF-6D utility scores was normal (P = 0.362), while that
of EQ-5D was bimodal (P < 0.001). Table 2 presents the distri-
bution of EQ-5D and SF-6D results within each domain. The
strong ceiling effect was observed in almost all domains except
pain/discomfort domain of EQ-5D, and the highest percentage of
ceiling effect appeared at mobility (97.0%), self-care (100%),
and usual activities (93.7%). Similarly, the ceiling effect occurred
at physical functioning (51.9%), role limitation (38.4%), and
social functioning (55.6%) domains of SF-6D. Although no ﬂoor
effect was observed, a noticeable percentage (7.1%) of patients
scored at ﬂoor level of anxiety/depression domain of EQ-5D.
Construct Validation
Convergent validity was demonstrated by the moderate to strong
correlation coefﬁcients (range: 0.422–0.548, P < 0.001) for three
of ﬁve a priori hypotheses in both EQ-5D and SF-6D (Table 3).
Correlations between utility of these two instruments with
EQ-VAS was weak, meanwhile, NIH-CPSI pain and urinary
scores correlated weakly with EQ-5D usual activity and SF-6D
role limitation.
Table 4 presents the univariate analyses results for EQ-5D and
SF-6D utility scores among multiple subgroups. Hypotheses for
known-group discriminative validity that both EQ-5D and SF-6D
utility scores would decrease monotonically with increasing NIH-
CPSI and decreasing EQ-VAS score levelswere fulﬁlled.Moreover,
both measures discriminated between the presence of other
chronic diseases, and not that of acute diseases. No signiﬁcant
difference in utility scores was observed among variables for social
economic status in univariate analyses for both instruments.
Sensitivity of EQ-5D and SF-6D
RE statistic calculation showed that SF-6D had 9.7% higher
efﬁciency at detecting difference between patients with mild and
moderate to severe CP symptom (Table 5). Sensitivity analysis
showed that recalculated RE statistic increased to 1.199, which
suggested that SF-6D is 19.9% more efﬁcient than EQ-5D.
Furthermore, the AUC scores of both instruments above 0.5
with statistical signiﬁcance suggested that they are able to detect
the difference between patients with mild and moderate to severe
CP symptom (Table 5). Sensitivity analysis was also performed,
and AUC score of EQ-5D decrease from 0.820 to 0.758 with cut
point changed to the median NIH-CPSI score, while AUC score
of SF-6D only decreased 0.005 unit.
Level of Agreement between EQ-5D and SF-6D
As shown in Table 6, EQ-5D utility scores were generally lower
than SF-6D, but the differences were not statistically signiﬁcant.
Spearman’s correlation coefﬁcient between the two instruments
was moderate (0.495) for all patients, but poor agreement
between them was observed with ICC (0.444). Moreover, the
level of correlation and ICC demonstrated a wide range (r:
0.288–0.825, ICC: 0.218–0.630) according to different social
economical and clinical factors.
Bland–Altman analysis indicated that the 95% limits of
agreement between EQ-5D and SF-6D ranged from -0.279 to
0.253, and over 95% points lies within limits (Fig. 1). The two
instruments did not demonstrate consistently similar measure
because there was a level of disagreement that includes reported
clinically important difference of up to 0.074 of EQ-5D and
0.033 of SF-6D [29,30]. Moreover, a systematic variation in the
utility difference of EQ-5D and SF-6D scores was observed, with
higher SF-6D at lower mean utility, and lower SF-6D at higher
mean utility scores.
Factors Affecting Utility Difference between EQ-5D
and SF-6D
As shown in Table 7, the multiple linear regression model with
difference between EQ-5D and SF-6D as the dependent variable,
CP symptom severity measured with NIH-CPSI scores attained
statistical signiﬁcance; however, the magnitudes of the inﬂuence
was very small (coefﬁcient -0.004, P = 0.014), while similar
result was observed at 7–12 years education level variable
Table 2 Distribution of EQ-5D and SF-6D results within each domain*
EQ-5D (%)
Level M SC UA PD AD
1 97.0 100.0 93.7 17.9 30.6
2 3.0 0.0 6.3 81.3 62.3
3 0.0 0.0 0.0 0.7 7.1
SF-6D (%)
Level PF RL SF P MH V
1 51.9 38.4 55.6 7.8 11.2 7.5
2 39.2 14.9 27.2 43.3 43.3 42.2
3 8.6 26.1 14.6 33.6 33.6 34.3
4 0.0 20.5 1.9 13.1 8.6 12.7
5 0.0 / 0.7 1.5 3.4 3.4
6 0.4 / / 0.7 / /
*EQ-5D dimensions: M, mobility; SC, self-care; UA, usual activities PD, pain/discomfort; AD,
anxiety/depression. SF-6D dimensions: PF, physical functioning RL, role limitation; SF, social
functioning; P, pain; MH, mental health;V, vitality.
Level in mold is in bold.
EQ-5D, EuroQol; SF-6D, Short Form 6D.
Table 3 Correlations between EQ-5D or SF-6D and NIH-CPSI or
EQ-VAS
NIH–CPSI
EQ-VASPain Urinary Quality of life Total
EQ-5D
Utility -0.474** -0.163* -0.487** -0.548** 0.264**
M 0.007 0.125* 0.119 0.100 -0.043
SC — — — — —
UA 0.062 0.066 0.109 0.086 -0.104*
PD 0.422** 0.068 0.209* 0.382** -0.068
AD 0.285** 0.127* 0.470** 0.409** -0.313*
SF-6D
Utility -0.431** -0.215** -0.486** -0.537** 0.340**
PF 0.231** 0.078 0.280** 0.297** -0.159*
RL 0.346** 0.212** 0.384** 0.447** -0.292**
SF 0.240** 0.192* 0.456** 0.408** -0.218**
P 0.451** 0.083 0.400** 0.469** -0.077
MH 0.303** 0.169* 0.433** 0.405** -0.334**
V 0.236** 0.114 0.266** 0.283** -0.382**
*P < 0.05 (two-tailed); **P < 0.001 (two-tailed).
Hypothesized moderate-to-strong correlations were shaded. EQ-5D dimensions: M, mobil-
ity; SC, self-care; UA, usual activities; PD, pain/discomfort; AD, anxiety/depression. SF-6D
dimensions: PF, physical functioning; RL, role limitation; SF, social functioning; P, pain; MH,
mental health;V, vitality.
EQ-5D, EuroQol; EQ-VAS, EuroQol Visual Analog Scale; NIH-CPSI, National Institutes of
Health Chronic Prostatitis Symptom Index; SF-6D, Short Form 6D.
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(-0.036, P = 0.041). Other socioeconomic and clinical variables
were not associated with any statistically signiﬁcant differences.
Discussion
An advantage of measuring HRQoL with preference-based mea-
sures is that the utility scores elicited have an intuitive interpre-
tation and theoretical application in decision-making. Therefore,
using an appropriate and valid instrument to elicit the health
utility score becomes a key determinant in ensuring the quality of
decision made by the clinicians and policymakers in both patient
management and health technology assessment. In this study, we
provided the evidence of validity and sensitivity of EQ-5D and
SF-6D in Chinese patients with chronic prostatitis, and demon-
Table 4 Univariate analyses for SF-6D and EQ-5D utility scores within subgroups
n (%)
EQ-5D SF-6D
Mean (SD) P-value Mean (SD) P-value
Age (Years) 0.903 0.251
20–29 106 (39.6) 0.73 (0.16) 0.74 (0.09)
30–39 106 (39.6) 0.73 (0.15) 0.74 (0.10)
40–49 47 (17.5) 0.75 (0.12) 0.76 (0.10)
50–59 9 (3.4) 0.78 (0.09) 0.81 (0.04)
Place 0.402 0.357
Beijing 173 (64.6) 0.74 (0.14) 0.75 (0.09)
Kunming 95 (35.4) 0.72 (0.16) 0.75 (0.11)
Ethnicity 0.094 0.353
Ethnic minority 26 (9.7) 0.73 (0.19) 0.76 (0.12)
Nonethnic minority 242 (90.3) 0.73 (0.15) 0.75 (0.09)
Years of education 0.489 0.309
6 18 (6.7) 0.74 (0.13) 0.72 (0.10)
7–12 118 (44.0) 0.71 (0.17) 0.75 (0.11)
12 132 (49.3) 0.75 (0.13) 0.75 (0.08)
Marriage status 0.643 0.605
Married 164 (61.2) 0.73 (0.14) 0.75 (0.10)
Nonmarried 104 (28.8) 0.74 (0.16) 0.74 (0.09)
Working status 0.062 0.111
Working 218 (81.3) 0.74 (0.15) 0.75 (0.09)
Not working 50 (18.7) 0.70 (0.17) 0.72 (0.10)
Months with CP 0.626 0.178
6 106 (39.5) 0.73 (0.16) 0.75 (0.10)
7–12 55 (20.5) 0.74 (0.12) 0.76 (0.08)
13–18 39 (14.6) 0.73 (0.15) 0.74 (0.09)
19–24 26 (9.7) 0.76 (0.12) 0.78 (0.10)
24 42 (15.7) 0.73 (0.17) 0.72 (0.11)
NIH-CPSI <0.001 <0.001
0–14 67 (25.0) 0.83 (0.08) 0.81 (0.08)
15–29 194 (72.4) 0.71 (0.15) 0.73 (0.09)
30–43 7 (2.6) 0.59 (0.24) 0.60 (0.10)
EQ-VAS 0.001 <0.001
<65 98 (36.6) 0.68 (0.18) 0.73 (0.07)
65–79 88 (32.8) 0.74 (0.13) 0.73 (0.07)
80–89 46 (17.2) 0.79 (0.08) 0.80 (0.07)
90–100 36 (13.4) 0.79 (0.10) 0.80 (0.11)
Presence of chronic medical
condition
0.001 0.002
Yes 59 (22) 0.71 (0.15) 0.73 (0.00)
No 209 (78) 0.74 (0.15) 0.73 (0.07)
Presence of acute medical
condition
0.455 0.451
Yes 135 (50.4) 0.74 (0.14) 0.74 (0.14)
No 133 (49.6) 0.73 (0.16) 0.75 (0.10)
EQ-5D, EuroQol; EQ-VAS, EuroQol Visual Analog Scale; NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; SF-6D, Short Form 6D.
Table 5 Efﬁciency of EQ-5D and SF-6D to detect clinically relevant difference
Measure NIH-CPSI n Mean (SD)
t Test
RE
ROC curve
t statistic P-value AUC 95% CI
EQ-5D 14 67 0.83 (0.08) 6.265 <0.001 1.000 0.820* (0.765, 0.876)
15 201 0.70 (0.15)
SF-6D 14 67 0.81 (0.08) 6.561 <0.001 1.097† 0.757* (0.691, 0.822)
15 201 0.73 (0.09)
EQ-5D 18 138 0.79 (0.10) 7.104 <0.001 1.000 0.758* (0.701, 0.805)
19 130 0.67 (0.17)
SF-6D 18 138 0.79 (0.08) 7.779 <0.001 1.199† 0.752* (0.695, 0.810)
19 130 0.70 (0.09)
*P < 0.001 indicates that AUC statistically signiﬁcantly greater than 0.5.
†Reference is EQ-5D measure.
AUC, area under ROC curves; CI, conﬁdence interval; EQ-5D, EuroQol; EQ-VAS, EuroQolVisual Analog Scale; NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; RE,
relative efﬁciency; ROC, receiver operating characteristic SF-6D, Short Form 6D.
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Table 6 Comparison of EQ-5D and SF-6D utility scores for all patients and several subgroups
n
Mean (SD) Median (IQR)
P-value† ICC SpearmanEQ-5D SF-6D EQ-5D SF-6D
All patients 268 0.73 (0.15) 0.75 (0.10) 0.73 (0.07) 0.76 (0.14) 0.627 0.444 0.495**
Age (years)
20–29 106 0.73 (0.16) 0.74 (0.09) 0.73 (0.07) 0.74 (0.13) 0.876 0.425 0.475**
30–39 106 0.73 (0.15) 0.74 (0.10) 0.76 (0.07) 0.73 (0.14) 0.893 0.460 0.518**
40–59 56 0.75 (0.11) 0.76 (0.10) 0.73 (0.07) 0.76 (0.15) 0.473 0.446 0.450**
Place
Beijing 173 0.74 (0.14) 0.75 (0.09) 0.73 (0.07) 0.76 (0.12) 0.455 0.398 0.424**
Kunming 95 0.72 (0.16) 0.75 (0.11) 0.73 (0.07) 0.79 (0.16) 0.104 0.505 0.602**
Ethnicity
Ethnic minority 26 0.73 (0.19) 0.76 (0.12) 0.80 (0.08) 0.78 (0.20) 0.388 0.630 0.461**
Nonethnic minority 242 0.73 (0.15) 0.75 (0.09) 0.73 (0.07) 0.76 (0.14) 0.822 0.412 0.578**
Years of education
6 18 0.74 (0.13) 0.72 (0.10) 0.73 (0.07) 0.73 (0.10) 0.157 0.406 0.825**
7–12 118 0.71 (0.17) 0.75 (0.11) 0.73 (0.07) 0.77 (0.15) 0.028 0.508 0.631**
12 132 0.75 (0.13) 0.75 (0.08) 0.73 (0.07) 0.75 (0.13) 0.357 0.361 0.342**
Marriage status
Married 164 0.73 (0.14) 0.75 (0.10) 0.73 (0.07) 0.76 (0.14) 0.475 0.218 0.535**
Nonmarried 104 0.74 (0.16) 0.74 (0.09) 0.73 (0.07) 0.76 (0.14) 0.404 0.500 0.439**
Working status
Working 218 0.74 (0.15) 0.75 (0.09) 0.73 (0.07) 0.76 (0.14) 0.874 0.409 0.467**
Not working 50 0.70 (0.17) 0.72 (0.10) 0.73 (0.07) 0.73 (0.13) 0.496 0.539 0.622**
Months with CP
6 106 0.73 (0.16) 0.75 (0.10) 0.73 (0.07) 0.76 (0.13) 0.236 0.436 0.353**
7–12 55 0.74 (0.12) 0.76 (0.08) 0.73 (0.07) 0.76 (0.10) 0.497 0.385 0.474**
13–18 39 0.73 (0.15) 0.74 (0.09) 0.73 (0.07) 0.73 (0.13) 0.494 0.418 0.530*
19–24 26 0.76 (0.12) 0.78 (0.10) 0.80 (0.07) 0.76 (0.13) 0.402 0.541 0.512*
24 42 0.73 (0.17) 0.72 (0.11) 0.73 (0.07) 0.73 (0.20) 0.268 0.481 0.673**
NIH-CPSI
0–14 67 0.83 (0.08) 0.81 (0.08) 0.80 (0.08) 0.82 (0.10) 0.368 0.285 0.382**
15–43 201 0.70 (0.15) 0.73 (0.09) 0.73 (0.02) 0.73 (0.12) 0.309 0.379 0.38**
EQ-VAS
<65 98 0.68 (0.18) 0.73 (0.07) 0.72 (0.09) 0.70 (0.12) 0.373 0.379 0.488**
65–79 88 0.74 (0.13) 0.73 (0.07) 0.74 (0.09) 0.76 (0.13) 0.369 0.441 0.506**
80–89 46 0.79 (0.08) 0.80 (0.07) 0.78 (0.08) 0.77 (0.11) 0.764 0.406 0.639**
90–100 36 0.79 (0.10) 0.80 (0.11) 0.81 (0.09) 0.82 (0.11) 0.296 0.273 0.288
Presence of chronic medical condition
Yes 59 0.71 (0.15) 0.73 (0.00) 0.71 (0.09) 0.71 (0.14) 0.76 0.296 0.326**
No 209 0.74 (0.15) 0.73 (0.07) 0.76 (0.10) 0.76 (0.13) 0.479 0.470 0.503**
Presence of acute medical condition
Yes 135 0.74 (0.14) 0.74 (0.14) 0.73 (0.07) 0.76 (0.14) 0.597 0.361 0.486**
No 133 0.73 (0.16) 0.75 (0.10) 0.73 (0.07) 0.76 (0.12) 0.211 0.517 0.478**
*P < 0.05 (two-tailed); **P < 0.001 (two-tailed).
†Paired comparisons of EQ-5D and SF-6D utility scores were made with Wilcoxon’s signed-rank test.
EQ-5D, EuroQol; EQ-VAS, EuroQol Visual Analog Scale; ICC, intraclass correlation coefﬁcient; IQR, interquartile range; NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom
Index; SF-6D, Short Form 6D.
Figure 1 Bland-Altman plot of difference in utility scores between EQ-5D and
SF-6D.
Table 7 Multiple linear regression analyses for utility difference
between EQ-5D and SF-6D*
Independent variables
Utility difference
Coefﬁcient (95% CI) P-value
Age (Years) 0 (-0.002, 0.002) 0.871
Beijing† 0.017 (-0.019, 0.053) 0.348
Ethnic minority 0.018 (-0.039, 0.075) 0.540
Household size -0.003 (-0.018, 0.011) 0.646
Years of education
6 0.029 (-0.042, 0.101) 0.421
7–12 -0.036 (-0.070, -0.001) 0.041
12 0.000 0.000
Married -0.017 (-0.052, 0.019) 0.359
Working 0.004 (-0.039, 0.047) 0.861
Months with CP 0.009 (-0.002, 0.020) 0.101
NIH-CPSI -0.004 (-0.007, 0) 0.014
EQ-VAS 0.001 (0, 0.002) 0.297
Presence of chronic medical condition 0.009 (-0.031, 0.049) 0.663
Presence of acute medical condition 0.018 (-0.014, 0.050) 0.273
*SF-6D is the subtrahend.
†Reference group is Kunming.
CI, conﬁdence interval; EQ-5D, EuroQol; EQ-VAS, EuroQol Visual Analog Scale; NIH-CPSI,
National Institutes of Health Chronic Prostatitis Symptom Index; SF-6D, Short Form 6D.
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strated it is feasible and acceptable to elicit the utility score with
these two instruments. Moreover, these two instruments show
similar, but not identical performance, especially at individual-
level. This head-to-head comparison shed some light on the
choice of preference-based HRQoL instruments for CP patients.
To our knowledge, this is the ﬁrst study evaluating the validity
and performance of preference-based HRQoL measures in CP
patients.
In our study, we choose Beijing, the capital of China in the
north, and Kunming, a middle size city in the south, to increase
the power, representativeness and the generalizability of the
results. Even though there were more subjects recruited from
Beijing, most of the patients’ characteristics were representative
of these two cities that have different economic and demographic
background. Furthermore, it was shown that the location does
not affect the validity of the results, and thus better generaliz-
ability of the results can be implied.
The convergent validity for EQ-5D and SF-6D was demon-
strated through their moderate-to-strong correlations with NIH-
CPSI, a validated instrument for CP, and “known-group”
validation further support the discriminative validation of
EQ-5D and SF-6D. The correlations between EQ-5D and SF-6D
with NIH-CPSI pain score are obviously higher than the corre-
lations of them with urinary score. This is in consistent with the
ﬁnding from Wenninger et al. that the pain scale was the only
physical symptom that signiﬁcantly contributed toward the sick-
ness impact, but not urinary symptoms [31]. Noticeably, the
strong ceiling effect of EQ-5D at mobility, self-care, and usual
activities domains might attenuate the correlation coefﬁcients.
The similar ceiling effects also occur in SF-6D physical function-
ing, role limitation, and social functioning domains, but com-
pared with EQ-5D, they were not so severe. A possible
explanation is that the subjects enrolled in this study were out-
patients, and most of them were experiencing mild to moderate
symptom, which may increase the ceiling effects. In addition, the
ceiling effects may arise when test problems are not the main
aspects impaired in the measured condition.
Mean SF-6D utility scores exceeded mean EQ-5D scores by
0.02 with no statistically signiﬁcance. The magnitude of differ-
ence is smaller than the differences reported in other disease
groups or general population [24,29,32,33]. This high degree of
similarity in utility scores might further support their convergent
validity in CP patients. However, although the EQ-5D and SF-6D
group scores were similar, the ICC analyses and Bland–Altman
plot revealed the inconsistence of these two measures at indi-
vidual level. From the Bland–Altman plot, we can tell that the
differences between EQ-5D and SF-6D were split into two groups
by mean utility score around 0.6. It is probably because of the
speciﬁc UK scoring algorithm of EQ-5D, in which if any dimen-
sion is at level 3, a N3 term will be included. The existence of N3
term can also lead to the bimodal distribution of EQ-5D utility
scores, whereas distribution of SF-6D was normal [29,33]. Nev-
ertheless, N3 term is not the only reason for the individual-level
discrepancy between EQ-5D and SF-6D, because only 21
patients (7.8%) reported extreme level in EQ-5D. Multiple linear
regression analysis showed that severity of symptom and educa-
tion level was the possible predictors for the utility differences.
However, the very small magnitudes of the inﬂuence suggested
that larger studies are needed to conﬁrm and further clarify our
ﬁndings. Consistent with the ﬁndings by Wee et al. that other
social economic factors had no signiﬁcant association with utility
differences [32], this suggested that the paired application of
instruments is feasible.
Even though both EQ-5D and SF-6D were demonstrated to
be valid and sensitive in CP patients, some comments need to be
made about the recommendation for them. First, although both
measures can distinguish patients with different severity of
symptom and self-reported health status, RE and ROC analysis
showed that SF-6D is more efﬁcient to detect clinically relevant
difference of CP patients. Second, even these two instruments are
all designed to measure the generic HRQoL and produce prefer-
ence index, their health descriptive systems, methods of eliciting
preferences, and scoring functions are different. SF-6D includes
broader aspects of HRQoL, such as role and social functioning,
and has more response level for each domain. This can make the
description of health status more comprehensive, and patients
would be more likely to ﬁnd the best description for their status.
In fact, the call for more response options to EQ-5D has been
addressed before [33], and ﬁve-level version of EQ-5D is under
development [34]. Third, EQ-5D is known to have strong ceiling
effects [14], and this may limit its ability to discriminate between
patients with mild to moderate symptom. Finally, the distribution
of EQ-5D scores was bimodal, whereas that of the SF-6D was
normal, leading to individual-level discrepancy of their utility
scores to some extent and raising concerns regarding the scoring
algorithm of the EQ-5D, which needs further evaluation. Even-
tually, with better HRQoL dimension coverage, greater sensitiv-
ity, lower ceiling effect, and more rational distribution, SF-6D is
shown to be the more appropriate choice in CP patients com-
pared with EQ-5D in our current study.
Naturally, the results of this study need to be interpreted in
the light of several possible limitations. The ﬁrst limitation was
that we did not examine the longitudinal response and reliability
of EQ-5D and SF-6D, for which are also important psychometric
characteristics of any HRQoL instrument. Although sensitive
measures is usually considered to be reliable [26], longitudinal
study is necessary for the validation of them in CP patients, as
this is a chronic disease. Second, the relatively small sample size
of CP patients with severe symptom (NIH-CPSI scores 31–43,
2.6%) might aggregate the high ceiling effect observed. Third,
according to the clinical diagnosis criteria practiced in China, we
cannot separate NIH II and NIH III type of CP in our study
subjects, hence this could potentially introduce systematic bias
resulting from the possible differences of patients’ experience.
However, evidence showed that inclusion of NIH II CP in the
analysis would not have effect on the quality of life analysis [35],
suggesting that it is possible to achieve equivalence of the
symptom impact on the HRQoL of these two types of CP. Nev-
ertheless, researchers and clinicians are encouraged to consider
the effect of CP classiﬁcation on the utility index measure when
adopting EQ-5D and SF-6D as outcome measures. Further
research with larger sample size and more strict diagnosis criteria
is needed to establish the benchmark of utility score for CP
patients and determine other psychometric properties, such as
longitudinal response and reliability.
Conclusion
In conclusion, EQ-5D and SF-6D are demonstrated to be valid and
sensitive preference-based HRQoL measures in Chinese CP
patients, with SF-6D showing better HRQoL dimension coverage,
greater sensitivity, lower ceiling effect. and more rational distri-
bution. Further research is needed to determine other psychomet-
ric properties, such as longitudinal response and reliability.
Source of ﬁnancial support: No funding was received for the conduction of
the present study.
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